Key Points
- CEO Ugur Sahin sold 41,000 BioNTech shares at an average price of $99.45, generating approximately $4.08 million. The transaction was conducted under a pre-arranged Rule 10b5-1 plan, leaving him with 602,209 shares.
- BioNTech recently reported weaker-than-expected quarterly results, including a $2.53 loss per share and revenue of $122.31 million, down 59.5% year over year. Analysts nevertheless maintain a consensus “Moderate Buy” rating with a $126 price target.
- Positive Phase 3 data for cancer drug candidate gotistobart, which nearly doubled median overall survival in previously treated lung-cancer patients, lifted BNTX shares by as much as approximately 6.4% and supports the company’s strategy to expand beyond COVID-19 vaccines.
BioNTech SE Sponsored ADR (NASDAQ:BNTX - Get Free Report) CEO Ugur Sahin sold 41,000 shares of the company's stock in a transaction dated Monday, September 14th. The shares were sold at an average price of $99.45, for a total transaction of $4,077,450.00. Following the completion of the transaction, the chief executive officer owned 602,209 shares in the company, valued at approximately $59,889,685.05. This trade represents a 6.37% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Ugur Sahin also recently made the following trade(s):
- On Friday, September 11th, Ugur Sahin sold 45,000 shares of BioNTech stock. The stock was sold at an average price of $96.93, for a total transaction of $4,361,850.00.
- On Thursday, September 10th, Ugur Sahin sold 20,500 shares of BioNTech stock. The stock was sold at an average price of $96.31, for a total value of $1,974,355.00.
- On Wednesday, September 9th, Ugur Sahin sold 36,000 shares of BioNTech stock. The stock was sold at an average price of $97.78, for a total value of $3,520,080.00.
- On Tuesday, September 8th, Ugur Sahin sold 37,000 shares of BioNTech stock. The shares were sold at an average price of $99.20, for a total value of $3,670,400.00.
- On Friday, September 4th, Ugur Sahin sold 31,500 shares of BioNTech stock. The stock was sold at an average price of $103.52, for a total value of $3,260,880.00.
- On Thursday, September 3rd, Ugur Sahin sold 45,000 shares of BioNTech stock. The stock was sold at an average price of $102.85, for a total value of $4,628,250.00.
BioNTech Stock Performance
NASDAQ:BNTX opened at $98.86 on Tuesday. The stock has a 50 day simple moving average of $97.08 and a 200 day simple moving average of $95.19. The stock has a market cap of $25.00 billion, a P/E ratio of -12.63 and a beta of 1.29. BioNTech SE Sponsored ADR has a 1-year low of $79.52 and a 1-year high of $124.00. The company has a current ratio of 7.85, a quick ratio of 7.80 and a debt-to-equity ratio of 0.01.
BioNTech (NASDAQ:BNTX - Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($2.53) EPS for the quarter, missing analysts' consensus estimates of ($2.40) by ($0.13). The firm had revenue of $122.31 million during the quarter, compared to analyst estimates of $180.18 million. BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The business's quarterly revenue was down 59.5% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.60) earnings per share. Research analysts anticipate that BioNTech SE Sponsored ADR will post -6.33 earnings per share for the current year.
Analyst Ratings Changes
A number of research firms recently commented on BNTX. Citigroup lowered their price target on shares of BioNTech from $130.00 to $125.00 and set a "buy" rating on the stock in a research report on Wednesday, August 5th. Jefferies Financial Group reissued a "buy" rating on shares of BioNTech in a report on Monday, June 1st. Sanford C. Bernstein restated a "market perform" rating on shares of BioNTech in a research report on Friday, June 5th. UBS Group raised shares of BioNTech from a "neutral" rating to a "buy" rating and raised their target price for the stock from $117.00 to $135.00 in a report on Wednesday, May 27th. Finally, BMO Capital Markets downgraded shares of BioNTech from an "outperform" rating to a "market perform" rating and dropped their price target for the company from $128.00 to $105.00 in a research report on Tuesday, September 8th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, BioNTech presently has a consensus rating of "Moderate Buy" and a consensus price target of $126.00.
Get Our Latest Stock Analysis on BNTX
Key Headlines Impacting BioNTech
Here are the key news stories impacting BioNTech this week:
- Positive Sentiment: BioNTech and partner OncoC4 reported that gotistobart nearly doubled median overall survival compared with standard chemotherapy in previously treated patients with squamous non-small-cell lung cancer. The Phase 3 PRESERVE-003 trial evaluated patients whose disease had progressed after immunotherapy and chemotherapy, supporting the drug’s potential as a differentiated oncology treatment. BioNTech and OncoC4 present updated gotistobart data
- Positive Sentiment: The survival results prompted reports that BNTX shares rose as much as approximately 6.4%. Investors appear to be viewing the data as a potentially important validation of BioNTech’s strategy to expand beyond COVID-19 vaccines and build an oncology pipeline. BioNTech says lung cancer candidate prolonged lives in trial
- Neutral Sentiment: Gotistobart, also known as BNT316 or ONC-392, is an investigational CTLA-4-targeting immunotherapy designed to reduce regulatory T cells in tumors and restore anti-tumor immune activity. The data are encouraging, but the treatment still faces further regulatory and clinical review before it can generate commercial revenue. BioNTech gotistobart overall survival data
- Negative Sentiment: CEO Ugur Sahin sold a combined 86,000 BioNTech shares for approximately $8.44 million across September 11 and September 14, reducing his holdings by roughly 13% in total. Both transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which limits the bearish signal, but the sales may still weigh modestly on investor sentiment. SEC insider transaction filing
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the stock. Flossbach Von Storch SE acquired a new position in BioNTech in the second quarter valued at about $207,142,000. BNP Paribas Financial Markets grew its stake in BioNTech by 43.0% during the fourth quarter. BNP Paribas Financial Markets now owns 1,578,094 shares of the company's stock worth $150,235,000 after buying an additional 474,796 shares in the last quarter. Bank of America Corp DE increased its holdings in BioNTech by 22.6% in the 1st quarter. Bank of America Corp DE now owns 903,029 shares of the company's stock valued at $80,261,000 after buying an additional 166,432 shares during the period. First Trust Advisors LP increased its holdings in BioNTech by 116.0% in the 1st quarter. First Trust Advisors LP now owns 839,991 shares of the company's stock valued at $74,658,000 after buying an additional 451,124 shares during the period. Finally, Assenagon Asset Management S.A. acquired a new position in shares of BioNTech in the 2nd quarter valued at approximately $39,385,000. Institutional investors own 15.52% of the company's stock.
BioNTech Company Profile
(
Get Free Report)
BioNTech SE is a biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. Its research platforms include messenger RNA, cell therapies, protein-based therapeutics, antibody therapies and small-molecule immunomodulators.
The company is best known for Comirnaty, its COVID-19 vaccine developed and commercialized globally in collaboration with Pfizer. BioNTech is also advancing a broad oncology pipeline that includes individualized and off-the-shelf cancer vaccines, antibody-based treatments, cell therapies and combination approaches designed to stimulate or direct the immune system against tumors.
BioNTech was founded in 2008 and is headquartered in Mainz, Germany.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
